Iron chelation for treatment of malaria;Chelation du fer dans la therapie antipaludique

Medecine Tropicale

Volumn 63, Issue 2, 2003, Pages 119-130

  Pradines, B ^a,b   Millet, J ^a,b   Henry, M ^a,b  

^a SERVICE DE SANTÉ DES ARMÉES   (France)

^b Institut Federatif de Recherche 48   (France)

Author keywords

Antimalarial drug; iron chelator; Malaria; Siderophore

Indexed keywords

ANTIMALARIAL AGENT; DEFEROXAMINE; HEMOGLOBIN; IRON CHELATING AGENT; SIDEROPHORE; IRON;

ANTIMALARIAL ACTIVITY; CYTOPLASM; DRUG RESEARCH; EXPERIMENTAL MODEL; HUMAN; IN VITRO STUDY; MALARIA; NONHUMAN; PARASITISM; PLASMODIUM FALCIPARUM; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; MALARIA FALCIPARUM; METABOLISM; PATHOGENICITY; PHYSIOLOGY;

ANIMALIA; PLASMODIUM FALCIPARUM;

ANIMALS; HUMANS; IRON; IRON CHELATING AGENTS; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM;

EID: 0142008820     PISSN: 0025682X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (144)

1. PRADINES B, VIAL H, OLLIARO P - Prophylaxie et traitement du paludisme: problèmes, récents développements et perspectives. Med Trop 2003; 63: 79-98.
2. PAYNE SM, FINKELSTEIN RA - The critical role of iron in host-bacterial interactions. J Clin Invest 1978; 61: 1428-1440.
3. WEINBERG ED - The role of iron in protozoan and fungal infectious diseases. J Eukaryot Microbiol 1999; 46: 231-238.
4. WEINBERG ED - Cellular regulation of iron assimilation. Q Rev Biol 1989; 64: 261-290.
5. WEINBERG ED - Cellular iron metabolism in health and disease. Drug Metab Rev 1990; 22: 531-579.
6. FINKELSTEIN RA, SCIORTINO CV, MCINTOSH MA - Role of iron in microbe-host interactions. Rev Infect Dis 1983; 5: 759-776.
7. WEINBERG ED - Iron and infection. Microbiol Rev 1978; 42: 45-66.
8. MURRAY MJ, MURRAY A, MURRAY CJ - The salutary effect of milk on amoebiasis and its reversal by iron. Br Med J 1980; 280: 1351-1352.
9. WEINBERG GA- Iron chelators as therapeutic agents against Pneumocystis carinii. Antimicrob Agents Chemother 1994; 38: 997-1003.
10. OPPENHEIMER SJ, MACFARLANE SB, MOODY JB et Coll - Effect of iron prophylaxis on morbidity due to disease: report on clinical studies in Papua New Guinea. Trans R Soc Trop Med Hyg 1986; 80: 596-602.
11. PEARSON HA, ROBINSON JE - The role of iron in host resistance. Adv Pediatr 1976; 23: 1-33.
12. MURRAY MJ, MURRAY AB, MURRAY MB, MURRAY CJ - The adverse effect of iron repletion on the course of certain infections. Br Med J 1978; 2: 1113-1115.
13. OPPENHEIMER SJ, MACFARLANE SB, MOODY JB, HARRISON C - Total dose iron infusion, malaria and pregnancy in Papua New Guinea. Trans R Soc Trop Med Hyg 1986; 80: 818-822.
14. MURRAY MJ, MURRAY NJ, MURRAY AB, MURRAY MB - Refeeding malaria and hyperferraemia. Lancet 1975; 1: 653-654.
15. OPPENHEIMER JL, GIBSON FD, MACFARLANE SB et Coll - Iron supplementation increases prevalence and effects of malaria: report on clinical studies in Papua New Guinea. Trans R Soc Trop Med Hyg 1986; 80: 603-612.
16. HARVEY P, HEYWOOD PF, NESHEIM MC et Coll - The effect of iron therapy on malarial infection in Papua New Guinean schoolchildren. Am J Trop Med Hyg 1989; 40: 12-18.
17. HERSCHKO C, PETO TE - Deferoxamine inhibition of malaria is independent of host iron status. J Exp Med 1988; 168: 375-387.
18. CARDOSO MA, FERREIRA MU, RIBEIRO GS, et Coll - Dietary iron supplementation does not aggravate experimental malaria in young rats. J Nutr 1996; 126: 467-475.
19. GOMA J, RENIA L, MILTGEN F, MAZIER D - Iron overload increases hepatic development of Plasmodium yoelii in mice. Parasitology 1996; 112: 165-168.
20. RODRIGUEZ MH, JUNGERY MH - A protein on Plasmodium falciparum-infected erythrocytes functions as a transferrin receptor. Nature 1986; 324: 388-391.
21. HALDAR K, HENDERSON CL, CROSS GA - Identification of the parasite transferrin receptor of Plasmodium falciparum infected erythrocytes and its acylatton via 1,2-diacyl-sn-glycerol. Proc Natl Acad Sci USA 1986; 83: 8565-8569.
22. POLLACK S, SCHNELLE V - Inability to detect transferrin receptors on Plasmodium falciparum parasitized red cells. Br J Haematol 1988; 68: 125-129.
23. SANCHEZ-LOPEZ R, HALDAR K - A transferrin-independent iron uptake activity on Plasmodium falciparum-infected and uninfected erythrocytes. Mol Biochem Parasitol 1992; 55: 9-20.
24. POLLACK S, FLEMMING J - Plasmodium falciparum takes up iron from transferrin. Br J Haematol 1984; 58: 289-293.
25. VAN ZYL RL, HAVLIK I, HEMPELMANN E et Coll - Malaria pigment and extracellular iron: possible target for iron chelating agents. Biochem Pharmacol 1993; 45: 1431-1436.
26. PETO TE, THOMPSON JL - A reappraisal of the effects of iron and desferrioxamine on the growth of Plasmodium falciparum in vitro: the unimportance of serum iron. Br J Haematol 1986; 63: 273-280.
27. CAZZOLA M, AROSiO P, BAROSI G et Coll - Ferritin in the red cells of normal subjects and patients with iron deficiency and iron overload. Br J Haematol 1983; 53: 659-665.
28. GABAY T, GINSBURG H - Haemoglobin denaturation and iron release in acidified red blood cell lysate. A possible source of iron for intraerythrocytic malaria parasites. Exp Parasitol 1993; 77: 261-272.
29. YINNON AM, THEANACHO EN, GRADY RW et Coll - Antimalarial effect of HBED and other phenolic and catecholic iron chelators. Blood 1989; 74: 2166-2171.
30. CABANTCHIK ZI, GLICKSTEIN H, GOLENSER J et Coll - Iron chelators: mode of action as antimalarials. Acta Haematol 1996; 95: 70-77.
31. SCOTT MD, RANZ A, KUYPERS FA et Coll - Parasite uptake of desferroxamine: a prerequisite for antimalarial activity. Br J Haematol 1990; 75: 598-602.
32. LOYEVSKY M, LYTTON SD, MESTER B et Coll - The antimalarial action of Desferal involves a direct access route to erythrocytic (Plasmodium falciparum) parasites. J Clin Invest 1993; 91: 218-224.
33. GABAY T, KRUGLIAK M, SHALMIEV G, GINSBURG H - Inhibition by antimalarial drugs of hemoglobin denaturation and iron release in acidified red blood cell lysates: a possible mechanism of their antimalarial effect? Parasitology 1994; 108: 371-381.
34. SRIVASTAVA P, PANDEY VC - Heme oxygenase and related indices in chloroquine-resistant and sensitive strains of Plasmodium berghei. Int J Parasitol 1995; 25: 1061-1064.
35. WOOD PA, EATON JW - Hemoglobin catabolism and host-parasite heme balance in chloroquine-sensitive and chloroquine-resistant Plasmodium berghei infections. Am J Trop Med Hyg 1993; 48: 465-472.
36. GINSBURG H, FAMIN O, ZHANG J, KRUGLIAK M - Inhibition of glutathione-dependent degradation of heme by chloroquine and amodiaquine as a possible basis for their antimalarial mode of action. Biochem Pharmacol 1998; 56: 1305-1313.
37. ZHANG J, KRUGLIAK M, GINSBURG H - The fate of ferriprotorphyrin IX in malaria infected erythrocytes in conjunction with the mode of action of antimalarial drugs. Mol Biochem Parasitol 1999; 99: 129-141.
38. GINSBURG H - Iron acquisition by Plasmodium spp. Parasitol Today 1999; 15: 466.
39. SUROLIA N, PADMANABAN G - De novo biosynthesis of heme offers a new chemotherapeutic target in the human malaria parasite. Biochem Biophys Res Commun 1992; 187: 744-750.
40. WILSON CM, SMITH AB, BAYLON RV - Characterization of the - aminolevulinate synthase gene homologue in Plasmodium falciparum. Mol Biochem Parasitol 1996; 75: 271-276.
41. BONDAY ZQ, TAKETANI S, GUPTA PD, PADMANABAN G - Heme biosynthesis by the malarial parasite. Import of delta-aminolevulinate dehydrase from the host red cell. J Biol Chem 1997; 272: 21839-21846.
42. LANCASTER CR, KROGER A - Succinate: quinone oxidoreductases: new insights from X-ray crystal structures. Biochim Biophys Acta 2000; 1459: 422-431.
43. RUZHEINIKOV SN, BURKE J, SEDELNIKOVA S, et Coll - Glycerol dehydrogenase, structure, specificity and mechanism of a family of polyol dehydrogenase. Structure 2001; 9: 789-802.
44. KAUFMANN F, LOVLEY DR - Isolation and characterization of a soluble NADPH-dependent Fe(III) reductase from Geobacter sulfurreducens. J Bacteriol 2001; 183: 4468-4476.
45. HAGEDOORN PL, SCHMIDT PP, ANDERSSON KK, Hagen WR, et Coll - the effect of substrate, dihydrobiopterin, and dopamine on the EPR spectroscopic properties and midpoint potential of the catalytic iron recombinant human phenylalanine hydroxylase. J Biol Chem 2001; 276: 22850-22856.
46. ARAVIND L, KOONIN EV - The DNA-repair protein AlkB, EGL-9, and leprecan define new families of 2-oxoglutarate- and iron-dependent dioxygenases. Genome Biol 2001; 2: research 0007.1-0007.8.
47. TURNBULL JJ, PRESCOTT AG, SCHOFIELD CJ, WILMOUTH RC - Purification, crystallization and preliminary X-ray diffraction of anthocyanidin synthase from Arabidopsis thaliana. Acta Crystallogr D Biol Crystallogr 2001; 57: 425-427.
48. PRESCOTT AG, LLOYD MD - The iron(II) and 2-oxoacid-dependent dioxygenases and their role in metabolism. Nat Prod Rep 2000; 17: 367-383.
49. CHAN JM, WU W, DEAN DR, SEEFELTD LC - Construction and characterization of a heterodimeric iron protein: defining roles for adenosine triphosphate in nitrogenase catalysis. Biochemistry 2000; 39: 7221-7228.
50. JOHNSON JL, NYBORG AC, WILSON PE et Coll - Analysis of steady state Fe and MoFe protein interactions during nitrogenase catalysis. Biochim Biophys Acta 2000; 1543: 24-35.
51. VERHAGEN MF, O'ROURKE TW, MENON AL, ADAMS MW - Heterologous expression and properties of the gamma-subunit of the Fe-only hydrogenase from Thermotoga maritima. Biochim Biophys Acta 2001; 1505: 209-219.
52. SORLIE M, CHRISTIASEN J, LEMON BJ, et Coll - Mechanistic features and structure of the nitrogenase alpha-Gln195 MoFe protein. Biochemistry 2001; 40: 1540-1549.
53. NISHINO T, OKAMOTO K - The role of the [2FE-2s] cluster centers in xanthine oxidoreductase. J Inorg Biochem 2000; 82: 43-49.
54. LUO GM, QI DH, ZHENG YG, et Coll - ESR studies on reaction of saccharide with the free radicals generated from the xanthine oxidase/hypoxanthine system containing iron. FEBS Lett 2001; 492: 29-32.
55. SERAVALLI J, ZHAO S, RAGSDALE SW - Mechanism of transfer of the methyl group from (6S)-methyltetrahydrofolate to the corrinoid/iron-sulfur protein catalysed by the methyltransferase from Clostridium thermoaceticum: a key in the Wood-Ljundahl pathway of acetyl-CoA synthesis. Biochemistry 1999; 38: 5728-5735.
56. DOUKOV T, SERAVALLI J, STEZOWSKI JJ, RAGSDALE SW - Crystal structure of a methyltetrahydrofolate- and corrinoid-dependent methyltransferase. Structure Fold Des 2000; 8: 817-830.
57. KHALEELI N, BUSBY RW, TOWNSEND CA - Site-directed mutagenesis and biochemical analysis of the endogenous ligands in the ferrous active site of clavaminate synthase. The His-3 variant of the 2-His-1-carboxylate model. Proteins 2000; 40: 590-612.
58. ZHOU J, KELLY WL, BACHMANN BO, et Coll - Spectroscopic studies of substrate interactions with clavaminate synthase 2, a multifunctional alpha-KG-dependent non-heme iron enzyme: correlation mechanisms and reactivities. J Am Chem Soc 2001; 123: 7388-7398.
59. WRIGGLESWORTH JM, BAUM H - The biochemical functions of iron. In «JACOBS A, WORWOOD M - Iron in Biochemistry and Medicine II». Academic Press ed., New York, 1980, pp 29-86.
60. RAVENTOS-SUAREZ C, POLLACK S, NAGEL RL - Plasmodium falciparum: inhibition of in vitro growth by desferrioxamine. Am J Trop Med Hyg 1982; 31: 919-922.
61. BEZKOROVAINY A - Biochemistry of non heme iron. Plenum Press ed., New York and London, 1980.
62. SCHEIBEL LW, SHERMAN IW - Metabolism and organellar function during various stages of life cycle: proteins, lipids, nucleic acids and vitamins. In WERNSDORFER W, MCGREGOR I - Malaria - Principles and Practice of Malariology. Churchill Livingstone ed., New York, 1988, pp 219-252.
63. SCHEIBEL LW, ASHTON SH, TRAGER W - Plasmodium falciparum: microaerophilic requirements in human red blood cells. Exp Parasitol 1979; 47: 410-418.
64. SCHEIBEL LW, ADLER A - Antimalarial activity of selected aromatic chelators. Mol Pharmacol 1980; 18: 320-325.
65. BAILEY-WOOD R, BLAYNEY LM, MUIR JR, JACOBS A - The effects of iron deficiency on rat liver enzymes. Br J Exp Pathol 1975; 56: 193-198.
66. COOK L, GRANT PT, KERMACK WO - Proteolytic enzymes of the erythrocytic forms of rodent and simian species of malaria plasmodia. Exp Parasitol 1961; 11: 372-379.
67. BECUWE P, GRATEPANCHE S, FOURMAUX MN et Coll - Characterization of iron-dependent endogenous superoxide dismutase of Plasmodium falciparum. Mol Biochem Parasitol 1996; 76: 125-134.
68. HEPPNER DG, HALLAWAY PE, KONTOGHIORGHES GJ, EATON JW - Antimalarial properties of orally active iron chelators. Blood 1988; 72: 358-361.
69. WHITEHEAD S, PETO TE - Stage-dependent effect of deferoxamine on growth of Plasmodium falciparum in vitro. Blood 1990; 76: 1250-1255.
70. HERSHKO C, THEANACHO EN, SPIRA DT et Coll - The effect of N-alkyl modification on the antimalarial activity of 3-hydroxypyridin-4-one oral iron chelators. Blood 1991; 77: 637-643.
71. VAN ZYL RL, HAVLIK I, MONTEAGUDO FSE - The combined effect of iron chelators and classical antimalarials on the in vitro growth of Plasmodium falciparum. J Antimicrob Chemother 1992; 30: 273-278.
72. JAMBOU R, GHOGOMU NA, KOUKA-BEMBA K, HENGY C - Activity of chloroquine and desferrioxamine in vitro against newly isolated Plasmodium falciparum and their antagonism in combination. Trans R Soc Trop Med Hyg 1992; 86: 11.
73. GLICKSTEIN H, BREUER B, LOYEVSKY M et Coll - Differential cytotoxicity of iron chelators on malaria infected cells versus mammalian cells. Blood 1996; 87: 4871-4878.
74. FRITSCH G, SAWATZKI G, TREUMER J et Coll - Plasmodium falciparum: inhibition in vitro with lactoferrin, desferrithiocin and desferricrocin. Exp Parasitol 1987; 63: 1-9.
75. SHANZER A, LIBMAN J, LYTTON SD et Coll - Reversed siderophores act as antimalarial agents. Proc Natl Acad Sci USA 1991; 88: 6585-6589.
76. LYTTON SD, CABANTCHIK ZI, LIBMAN J, SHANZER A - Reversed siderophores as antimalarial agents. II. Selective scavenging of Fe(III) from parasitized erythrocytes by an fluorescent derivative of Desferal. Mol Pharmacol 1991; 40: 584-590.
77. LYTTON SD, MESTER B, DAYAN I et Coll - Mode of action of iron(III) chelators as antimalarials: I. Membrane permeation properties and cytotoxic activity. Blood 1993; 81: 214-221.
78. SCHEIBEL LW, STANTON GG - Antimalarial activity of selected aromatic chelators. IV. Cation uptake of Plasmodium falciparum in the presence of oxines and siderochromes. Mol Pharmacol 1986; 30: 364-369.
79. SCHEIBEL LW, RODRIGUEZ S - Antimalarial activity of selected aromatic chelators. V. Localization of 59Fe in Plasmodium falciparum in the presence of oxines. Prog Clin Biol Res 1989; 313: 119-149.
80. PRADINES B, RAMIANDRASOA F, BASCO LK et Coll - In vitro activities of novel catecholate siderophore against Plasmodium falciparum. Antimicrob Agents Chemother 1996; 40: 2094-2098.
81. PRADINES B, ROLAIN JM, RAMIANDRASOA F et Coll - Iron chelators as antimalarial agents: in vitro activity of dicatecholate against Plasmodium falciparum. J Antimicrob Chemother 2002; 50: 177-187.
82. ROTHENEDER A, FRITSCHE G, HEINISCH L et Coll - Effects of synthetic siderophores on proliferation of Plasmodium falciparum in infected human erythrocytes. Antimicrob Agents Chemother 2002; 46: 2010-2013.
83. YANG YZI, RANZ A, PAN HZ et Coll - Daphnetin: a novel antimalarial agent with in vitro and in vivo activity. Am J Trop Med Hyg 1992; 46: 15-20.
84. CLARKE CJ, EATON JM - Hydrophobic iron chelators as new antimalarial drugs. Clin Res 1990; 38: 300A.
85. TSAFACK A, LOYEVSKY M, PONKA P, CABANTCHIK ZI - Mode of action of iron (III) chelators as antimalarials: IV. Potentiation of desferal action by benzoyl and isonicotinoyl hydrazone derivatives. J Lab Clin Med 1996; 127: 574-582.
86. LOYEVSKY M, JOHN C, ZALOUJNYI I, GORDEUK V - Aminothiol multidentate chelators as antimalarials. Biochem Pharmacol 1997; 54: 451-458.
87. JAIRAM KT, HAVLIK I, MONTEAGUDO FS - Possible mechanism of action of desferrioxamine and 2,2′-bipyridyl on inhibiting the in vitro growth of Plasmodium falciparum. Biochem Pharmacol 1991; 42: 1633-1634.
88. HAMMADI A, RAMIANDRASOA F, SINOU V et Coll - Cellular uptake of a catechol iron chelator and chloroquine into Plasmodium falciparum infected erythrocytes. Biochem Pharmacol 2003; 65: 1351-1360.
89. VERCELLOTTI GM, VAN ASBECK BS, JACOB HS - Oxygen radical-induced erythrocyte hemolysis by neutrophils. Critical role of iron and lactoferrin. J Clin Invest 1985; 76: 956-962.
90. CABANTCHIK ZI, KUTNER S, KRUGLIAK M, GINSBURG H - Anion transport inhibitors as suppressors of Plasmodium falciparum growth in in vitro cultures. Mol Pharmacol 1983; 23: 92-99.
91. SILFEN J, YANAI P, CABANTCHIK ZI - Bioflavonoid effects on in vitro cultures of Plasmodium falciparum. Inhibition of permeation pathways induced in the host cell membrane by the intraerythrocytic parasite. Biochem Pharmacol 1988; 37: 4269-4276.
92. PRADINES B, ROGIER C, FUSAIT et Coll - in vitro activities of antibiotics against Plasmodium falciparum are inhibited by iron. Antimicrob Agents Chemother 2001; 45: 1746-1750.
93. STAHEL E, MAZIER D, GUILLOUZO A et Coll - Iron chelators: in vitro inhibitory effect on the liver stage of rodent and human malaria. Am J Trop Med Hyg 1988; 39: 236-240.
94. MABEZA GF, LOYEVSKY M, GORDEUK VR, WEISS G - Iron chelation therapy for malaria: a review. Pharmacol Ther 1999; 81: 53-75.
95. NEILANDS JB - Siderophores: structure and function of microbial iron transport compounds. J Biol Chem 1995; 270: 26723-26726.
96. SINGH S, HIDER RC - Therapeutic iron-chelating agents. In «RICE EVANS CA, BURDON RH - Free radical damage and its control». Elsevier Science ed, New York, 1994, pp 189-216.
97. GOODWIN JF, WHITTEN CF - Chelation of ferrous sulfate solutions by desferrioxamine B. Nature 1965; 205: 281-283.
98. PONKA P, RICHARDSON DR, EDWARD JT, CHUBB FL - Iron chelators of the pyridoxal isonycotinoyl hydrazone class. Relationship of the lipophilicity of the apochelator to its ability to mobilize iron from reticulocytes in vitro. Can J Physiol Pharmacol 1994; 72: 659-666.
99. DOBBIN PS, HIDER RC - Iron chelation therapy. Chem Br 1990; 26: 565-568.
100. HOFFBRAND AV - Iron chelation therapy. Curr Opin Hematol 1995; 2: 153-158.
101. OLIVIERI NF, BRITTENHAM GM - Iron-chelating therapy and the treatment of thalassemia. Blood 1997; 89: 739-761.
102. MODELL B, BERDOUKAS V - The Clinical Approach to Thalassemia. Grune & Stratton ed., London 1984.
103. BRITTENHAM GM - Iron chelating agents. In «BRAIN MC, CARBONE PP - Current Therapy in Hematology Oncology 3». Mosby ed., St Louis, 1988, pp. 149-153.
104. SUMMERS M, JACOBS A, TUDWAY D et Coll - Studies in desferrioxamine and ferrioxaminemetabolism in normal and iron-loaded subjects. Br J Haematol 1979; 42: 547-555.
105. BASCO LK, LE BRAS J - in vitro activity of chloroquine and quinine in combination with desferrioxamine against Plasmodium falciparum. Am J Hematol 1993; 42: 389-391.
106. POUVELLE B, SPIEGEL R, HSIAO L et Coll - Direct access to serum macromolecules by intraerythrocytic malaria parasites. Nature 1991; 353: 73-75.
107. LOYEVSKY M, CABANTCHIK ZI - Antimalarial action of hydrophilic drugs: involvement of aqueous access routes to intracellular parasites. Mol Pharmacol 1994; 45: 446-452.
108. ATKINSON CT, BAYNE MT, GORDEUK VR et Coll - Stage-specific ultrastructural effects of desferrioxamine on Plasmodium falciparum in vitro. Am J Trop Med Hyg 1991; 45: 593-601.
109. NYHOLM S, MANN GJ, JOHANSSONAG, et Coll - Role of ribonucleotide reductase in inhibition of mammalian cell growth by potent iron chelators. J Biol Chem 1993; 268: 26200-26205.
110. CHEVION M, CHUANG L, GOLENSER J - Effects of zinc-desferrioxamine on Plasmodium falciparum in culture. Antimicrob Agents Chemother 1995; 39: 1902-1905.
111. VIPPAGUNTA SR, DORN A, BUBENDORF A, et Coll - Deferoxamine: stimulation of hematin polymerization and antagonism of its inhibition by chloroquine. Biochem Pharmacol 1999; 58: 817-824.
112. MOORMANN AM, HOSSLER PA, MESHNICK SR - Deferoxamine effects on Plasmodium falciparum gene expression. Mol Biochem Parasitol 1999; 98: 279-283.
113. POLLACK S, ROSSAN RN, DAVIDSON DE, ESCAJADILLO A - Desferrioxamine suppresses Plasmodium falciparum in aotus monkeys. Proc Soc Exp Biol Med 1987; 184: 162-164.
114. FRITSCH G, TREUMER J, SPIRA DT, JUNG A - Plasmodium vinckei: suppression of mouse infections with desferrioxamine B. Exp Parasitol 1985; 60: 171-174.
115. SCHLICHER EJAM, POSTMA NS, ZUIDEMA J et Coll - Preparation and characterisation of poly (D,L-lactic-co-glycolic acid) microspheres containing desferrioxamine. Int J Pharm 1997; 153: 235-245.
116. TRAORE O, CARNEVALE P, KAPTUE-NOCHE L et Coll - Preliminary report on the use of desferrioxamine in the treatment of Plasmodium falciparum malaria. Am J Hematol 1991; 37: 206-208.
117. MABEZA GF, BIEMBA G, GORDEUK VR - Clinical studies of iron chelators in malaria. Acta Haematol 1996; 95: 78-86.
118. GORDEUK VR, THUMA PE, BRITTENHAM GM et Coll - Iron chelation with desferrioxamine B in adults with asymptomatic Plasmodium falciparum malaria. Blood 1992; 79: 308-312.
119. GORDEUK VR, THUMA PE, BRITTENHAM GM et Coll - Iron chelation as a chemotherapeutic strategy for falciparum malaria. Am J Trop Med Hyg 1993; 48: 193-197.
120. BUNNAG D, POLTERA AA, VIRAVAN C et Coll - Plasmodicidal effect of desferrioxamine B in human vivax or falciparum malaria from Thailand. Acta Trop 1992; 52: 59-67.
121. GORDEUK V, THUMA P, BRITTENHAM G et Coll - Effect of iron chelation therapy on recovery from deep coma in children with cerebral malaria. N Engl J Med 1992; 327: 1473-1477.
122. THUMA PE, MABEZA GF, BIEMBA G, et Coll - Effect of iron chelation therapy on mortality in Zambian children with cerebral malaria. Trans R Soc Trop Med Hyg 1998; 92: 214-218.
123. MOLYNEUX ME, TAYLOR TE, WIRIMA JJ, BORGSTEIN A - Clinical features and prognostic indicators in paediatric cerebral malaria: a study of 131 comatose Malawian children. Q J Med New 1989; 71: 441-459.
124. CABANTCHIK ZI - Iron chelators as antimalarials - the biochemical basis of selective cytotoxicity. Parasitol Today 1995; 11: 73-78.
125. LYTTON SD, MESTER B, LIBMAN J et Coll - Mode of action of iron(III) chelators as antimalarials. II. Evidence for differential effects on parasite iron-dependent nucleic acid synthesis. Blood 1994; 84: 910-915.
126. LYTTON SD, LOYEVSKY M, MESTER B et Coll - in vivo antimalarial action of a lipophilic iron(III) chelator: suppression of Plasmodium vinckei infection by reversed siderophore. Am J Hematol 1993; 43: 217-220.
127. KONTOGHIORGHES GJ - 2-Hydroxypyridine-N-oxides: effective new chelators in iron mobilisation. Bioch Biophys Acta 1987; 924: 13-18.
128. PORTER JB, HIDER RC, HUEHNS ER - Update of the hydroxypyridinone oral iron-chelating agents. Semin Hematol 1990; 27: 95-100.
129. PORTER JB, GYPARAKI M, HUEHNS ER, HIDER RC - The relationship between the Iipophilicity of hydroxypyridid-4-one iron chelators and cellular iron metabolism using an hepatocyte culture model. Biochem Soc Trans 1986; 14: 1180.
130. KONTOGHIORGHES GJ, HOFFBRAND AV - Orally active alpha ketohydroxyl pyridine iron chelators intended for clinical use: in vivo studies in rabbits. Br J Haematol 1986; 62: 607-613.
131. KONTOGHIORGHES GJ, BARR J, NORTEY P, SHEPPARD L - Selection of a new generation of orally active α-ketohydroxypyridine iron chelators intented for use in the treatment of iron overload. Am J Hematol 1993; 42: 340-349.
132. PATTANAPANYASAT K, THAITHONG S, KYLE DE, et Coll - Flow cytometric assessment of hydroxypyridone iron chelators on in vitro growth of drug-resistant malaria. Cytometry 1997; 27: 84-91.
133. HERSHKO C, GORDEUK VR, THUMA PE et Coll - The antimalarial effect of iron chelators: studies in on animal models and in humans with mild falciparum malaria. J Inorg Biochem 1992; 47: 267-277.
134. MATSUI D, KLEIN J, HERMANN C et Coll - Relationship between the pharmacokinetics and iron excretion pharmacodynamics of the new oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with thalassemia. Clin Pharmacol Ther 1991; 50: 294-298.
135. OLIVIERI NF - Long-term therapy with deferiprone. Acta Haematol 1996; 95: 37-48.
136. MOHANTY D, GHOSH K, PATHARE AV, KARNAD D - Deferiprone (L1) as an adjuvant therapy for Plasmodium falciparum malaria. Indian J Med Res 2002; 115: 17-21.
137. DOUNGDEE P, SAREL S, WONGVISETSIRIKUL N, AVRAMOVICI-GRISARU S - Iron chelators of the pyridoxal 2-pyridyl hydrazone class. Part 4. pKa values of the chelators and their relevance to biological properties. J Chem Soc Perkin Trans 1995; 2: 319-323.
138. BRITTENHAM GM - Pyridoxal isonicotinoyl hydrazone: an effective iron-chelator after oral administration. Seminars Hematol 1990; 27: 112-116.
139. IHEANACHO EN, SAMUNI A, AVRAMOVICI-GRISARU S et Coll - Inhibition of Plasmodium falciparum growth by a synthetic iron chelator. Trans R Soc Trop Med Hyg 1990; 84: 213-216.
140. PRADINES B, RAMIANDRASOA F, ROLAIN JM et Coll - in vitro potentiation of antibiotics activities by a catecholate siderophore against Plasmodium falciparum chloroquine resistant parasites. Antimicrob Agents Chemother 2002; 46: 225-228.
141. TSAFACK A, GOLENSER J, LIBMAN J et Coll - Mode of action of iron(III) chelators as antimalarials. III. Overadditive effects in the combined action of hydroxamate-based agents on in vitro growth of Plasmodium falciparum. Mol Pharmacol 1995; 47: 403-409.
142. GOLENSER J, TSAFACK A, AMICHAI Y et Coll - Antimalarial action of hydroxamate-based iron chelators and potentation of desferrioxamine action by reversed siderophores. Antimicrob Agents Chemother 1995; 39: 61-65.
143. LASKEY JD, PONKA P, SCHULMAN HM - Control of heme synthesis during Friend cell differentiation: role of iron and transferrin. J Cell Physiol 1986; 129: 185-192.
144. GOLENSER J, DOMB A, TEOMIM D et Coll - The treatment of animal models of malaria with iron chelators by use of a novel polymeric device for slow drug release. J Pharmacol Exp Ther 1997; 281: 1127-1135.